Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Smoldering Multiple Myeloma 2Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Multiple Myeloma 1Multiple Endocrine Neoplasia 1Melanoma 1Lung Neoplasms 1Glioma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Dexamethasone 11Lenalidomide 9Calcium Dobesilate 5carfilzomib 4daratumumab 3isatuximab 2iberdomide 2elotuzumab 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Leflunomide 2Denosumab 2selinexor 1pomalidomide 1piperine 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1Simvastatin 1Nivolumab 1Metformin 1Melphalan 1IPH-2101 1Gene Expression Profiling 1Fatty Acids, Omega-3 1Cyclophosphamide 1Curcumin 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Smoldering Multiple Myeloma × Leflunomide × Clear all
NCT05014646 2026-04-30

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

City of Hope Medical Center

Phase 2 Active not recruiting
27 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT03952832 2019-11-14

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

City of Hope Medical Center

Phase 2 Withdrawn
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡